monster quarter increas pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
abbv- monster quarter still remain top larg cap pick
guidanc close vs consensu
rais ep guidanc midpoint sinc earn call revis adjust ep
guidanc
indic adjust tax rate vs consensu grow gradual yr
indic venclexta file aml regulatori feedback
discuss capit alloc board feb inc divi share repo updat provid
pt increas
increas humira nt lt estim
lower rova-t estim explan
increas revenu line reflect venclexta start break separ
thesi updat rova-t think see well posit attract valu regardless
outcom rova-t triniti studi one key new data readout
cours year compani reiter confid program although would
prefer go risk reward clear indic dont see downsid fail
investor may struggl trade around event base confid data
readout may read-through rest stemcentrx comfort treat
readout upsid option
track respect beat/miss
evr isi beat/misstot row net firstord analyt compani reportsnot mavyret consensu split us row therefor includ hcv totalabbv quarterli perform januari
commentari around product serial across quarter includ
serial guidanc updat
line revenueglob oper sale fx oper growth doubl growth growth rheum doubl digit derm gi cd/uc share ps hs major formulari chang leader across categoriesrobust market ra spa psoriasi crohn uc posit vari high singl digit tender time inventori half month half month half monthimbruvicaglob oper cll market share leader across line cll market cll market sharestrong del ger/frn/ashar loss price erosionmor performancecontribut contract cycl esp sharepar acccess across cover live usclos neg partnership account partnership partnership partnership account exchang hedg leverag rule equiti comp pronounc compani reportsviekiramavyretduopaabbv histor quarter perform commentaryadjust tax rateadjust epscreonadj gross marginadjust salesadjust sg salesoper margin januari
roll commentari around pipelin
oper fx minim fx compound-annual-growth-rate fx oper fx oper fx fx mid-high teensmid/high teensmid/high teensmid/high teen teenshigh teenslow teen yoyhumira ousmid-singl digitmid-singl fx approach mid-mid-singlepeak qmid-singl volum fx mid singlemid-single-digit imbruvica qhigh-singl prior qimbruvica w/w productsandrogen creon mid-high singl lupron synagi synthroid flatmavyret deliv multi-billion peakglob hcv equal split us ou market creon growth duodopa androgel zinbryta synagi lupron synthroid flatgross weak usd may impact qlower synagi expect tax increas next yearsadjust y/i non-cash non-cash sourc compani reportsannu guidanc start year unless indic januari
cgvhd fda decis fda approv soongvhd data cll w/ gazyva dlbcl w/ r-chop data near mcl later interim shine mcl mcl later abbvpotenti interim nhl interim nhl data readout dlbcl unfit cll/sll interim data cll studi young fit watch wait patient on-going data evalu mono/combo br/fcr young/fit watch/wait cllpotenti snda submiss mcl dlbcl potenti snda submiss mcl dlbcl murano r/r cll murano r/r cll murano r/r cll readout come monthssnda submiss r/r cll eu potenti approv venclexta r/r cllsnda submiss r/r cll complet expect approv cll studi on-going inc comb imbruvica older/comorbid data on-going studi initi studi mainten data aml mm submit snda aml potenti approv late myeloma aml on-going data pivot mm inhl dlbcl later ra data later ra studi ye next month beyond biolog failur cdmard ra pivot come month select beyond select-monotherapi launch ra pivot select-compar select- ra pivot bla submiss cd start u/c start cd ddw start start cd later a/ uc ad start uc start giant cell arter ad uc giant cell arter report full ad aad meet ad later ad on-going start u/c soonprogress studi cd uc ad ad later on-going psoriat arthriti cd also evalu psoriasi studi later launch psoriasi studi later launch psoriasi studi later file launch bla psoriasi bla psoriasi cd start start cd soon start u/c cd start uc cd uc cd expect begin studi uc start start start triniti triniti normal yr surviv file triniti sclc triniti triniti sclc data chemo rova-t opdivo yervoy sclc start taho sclc combo i/o data meru/taho combo i/o data meru/taho ongoingneuroendocrin basket studi data basket studi data sclc sclc sclc otherposs data neuroendocrin basket studi gbm data potenti gbm gbm potenti gbm data potenti gbm trial on-going file gbmongo gbm endometriosi file endometriosi endometriosi present asrm congress end octprior review grant pdufa expect expect fibroid toward fibroid fibroid us e/m could opioid pain build market educatemavyretus/eu approv approv approv expect greatest impact multi-billioncfroom improv benefit pt move toward mid phase novel program clinic alreadi clinic program clinic sever addit move clinic yearmultipl program advanc multipl modal target data colorect cancer data ovarian neoadjuv mbc nsclc advanc tnb nsclc fail data nsclcsourc compani reportsabbv product outlook commentari januari
deriv pt use dcf discount rate termin growth rate discount
rate standard rate appli across derisk biopharma compani reflect believ appropri return
sharehold termin growth rate reflect durabl natur compani biolog franchis
clearli humira domin product model still assum repres total model revenu
current framework biosimilar adopt chang humira method use patent fall multipl
biosimilar launch simultan creat pent-up precipit impact sale share could suffer rova-t
elagolix import pipelin program either stumbl share could see modest downsid
articl articl
time dissemin januari et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
